Post on 29-Jul-2016
description
CANCER DE MAMA TRIPLE NEGATIVO
Dra. Silvia Falcón Lizaraso Oncología Médica
Directora de la Unidad de Mama –Aliada Marzo 2016
Presented at the 2013 ASCO Annual Meeting. Presented data is the property of GBG and AGO-B.
pCR Rates by Subtype
37.9% 58.7%
0%
20%
40%
60%
80%
100%
PM PMCb
TNBC
36.3% 33.1%
0%
20%
40%
60%
80%
100%
PM PMCb
HER2-positive
P<0.05 n.s.
ypT0 ypN0
N=157 N=158 N=136 N=137
GeparSixto: Summary • Altera;ons of gBRCA or gRAD50/51 detectable in ≥ 15% of par;cipants with TNBC from GeparSixto trial
• pCR rates higher in pa;ents with family history of BC/OC (49%), gBRCA/RAD altera;ons (55%), or both risk factors (64%) compared with neither risk factor (40%)
• Increase in pCR rate with carbopla;n highest in pa;ents with family history (26%) and gBRCA/RAD altera;ons (23%)
• Germline muta;on status and family history may help iden;fy pa;ents who can benefit from adding carbopla;n to neoadjuvant chemotherapy
• Ques;ons remain on use of pla;num agents in standard neoadjuvant therapy (dose-‐dense AC followed by paclitaxel)
von Minckwitz G, et al. ASCO 2014. Abstract 1005.